Soligenix (Soligenix) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Jun. 09, 2024)

View and export this data going back to 1994. Start your Free Trial

What is Soligenix Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Soligenix's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Soligenix's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Soligenix's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Soligenix's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Soligenix's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

Soligenix (NAS:SNGX) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Soligenix Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Soligenix's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Soligenix (Soligenix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

0A6I:UK

Address

29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website

https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Executives

Timothy R. Cote	director	3529 TILDEN STREET, NW, WASHINGTON DC 20008
Richard Straube	officer: CMO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Christopher Schaber	director, officer: Chairman, CEO and President	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Jonathan L. Guarino	officer: Chief Financial Officer	100 WELLESLEY WAY, FREEHOLD NJ 07728
Oreola Donini	officer: CSO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Robert J. Rubin	director	7901 SPRINGER ROAD, BETHESDA MD 20817
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Mark E. Pearson	director, 10 percent owner	3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128
Preta Martina Cavazza	other: Former 10% Owner	VIA SUDAFRICA 20, ROME L6 00144
Enrico Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Francesca Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144